Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial

Keyphrases

• 6-minute Walk Distance (6MWD) 12%
• Acute Decompensated Heart Failure 100%
• Acute Heart Failure 12%
• Between-group Difference 25%
• Cardiac Function 12%
• Cardiac Metabolism 12%
• Cardiac Structure 12%
• Cardioprotection 12%
• Clinical Situation 12%
• Clinical Stability 100%
• Combined Events 12%
• Diabetes Status 12%
• Early Phase Clinical Trials 12%
• Global Rankings 12%
• Glucagon-like 37%
• Hazard Ratio 25%
• Heart Failure 50%
• Heart Failure with Preserved Ejection Fraction (HFpEF) 12%
• Hospitalization 12%
• Left Ventricular Ejection Fraction 37%
• Life Events 12%
• Liraglutide 100%
• March 2015 12%
• Mean Rank 12%
• N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) 25%
• Number of Deaths 12%
• Pathophysiology 12%
• Patients with Diabetes 12%
• Placebo 25%
• Placebo Groups 37%
• Placebo-controlled 12%
• Proportional Changes 12%
• Quality of Life 12%
• Randomized Clinical Trial 100%
• Ranking Score 12%
• Reduced Ejection Fraction 100%
• Rehospitalization 37%
• Subcutaneous Injection 12%
• Subgroup Analysis 12%
• Time Since Death 25%
• Treatment Assignment 12%
• Type 2 Diabetes Mellitus (T2DM) 25%

Medicine and Dentistry

• Acute Decompensated Heart Failure 12%
• Amino Terminal Sequence 25%
• Antidiabetic Agent 12%
• Brain Natriuretic Peptide 25%
• Cardiac Structure 12%
• Clinical Study 12%
• Congestive Heart Failure 100%
• Ejection Fraction 100%
• Glucagon-Like Peptide-1 Agonist 37%
• Hazard Ratio 25%
• Heart Function 12%
• Heart Left Ventricle Ejection Fraction 50%
• Heart Muscle Metabolism 12%
• Liraglutide 100%
• Maturity Onset Diabetes of the Young 25%
• Pathophysiology 12%
• Patient with Diabetes 12%
• Placebo 75%
• Quality of Life 12%
• Randomized Clinical Trials 100%
• Subcutaneous Injection 12%
• Subgroup Analysis 12%
• Time of Death 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Heart Failure 12%
• Antidiabetic Agent 12%
• Brain Natriuretic Peptide 25%
• Clinical Study 12%
• Congestive Heart Failure 100%
• Glucagon Like Peptide 1 Receptor Agonist 37%
• Liraglutide 100%
• Maturity Onset Diabetes of the Young 25%
• Pathophysiology 12%
• Placebo 75%
• Randomized Clinical Trial 100%
• Subcutaneous Injection 12%
• Time of Death 12%